Vivanza Biosciences Ltd Stock Price Today (NSE: VIVANZA)

Vivanza Biosciences Ltd

1.81+0.03 (+1.69%)
Market Open

Fundamental Score

...

Vivanza Biosciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Vivanza Biosciences Ltd share price today is 1.81, up +1.69% on NSE/BSE as of 19 June 2026. Vivanza Biosciences Ltd (VIVANZA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 8.80 (Cr). The 52-week high for VIVANZA share price is 2.72 and the 52-week low is 1.74. The company has a Return on Equity (ROE) of -15.58% and a debt-to-equity ratio of 2.20.

Vivanza Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
2.15
Low
1.75
Volume
22.9K
Change
-14.63%

Vivanza Biosciences Ltd share price chart: -14.63% return over the past month. 52-week high ₹2.72, 52-week low ₹1.74.

Vivanza Biosciences Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
1.781.811.781.8121.75K (Cr)
1.741.871.741.785.02K (Cr)
1.741.751.741.7493.77K (Cr)
1.771.771.751.7532.91K (Cr)
1.771.771.761.7715.84K (Cr)
1.771.811.771.7728.22K (Cr)
1.811.901.771.7727.19K (Cr)
1.811.821.811.8149.70K (Cr)
1.981.981.811.8112.37K (Cr)
1.831.841.831.848.73K (Cr)

Vivanza Biosciences Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
1.741.871.741.81+4.02%
2.012.151.741.74-13.43%
1.842.131.822.07+12.50%
2.042.041.751.76-13.73%
2.092.182.022.04-2.39%
2.202.311.982.06-6.36%
2.202.312.002.20+0.00%
1.962.721.952.20+12.24%
2.042.251.901.96-3.92%
2.102.221.982.04-2.86%
2.082.181.982.05-1.44%
2.102.202.022.04-2.86%

Returns & Performance

Poor

Return on Equity (ROE)

-15.58%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-2.77%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

1.94%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Vivanza Biosciences Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

20.02%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

2700.00%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

1745.33%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-5.02%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

2.20x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

0.07x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-2.09 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Vivanza Biosciences Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of VIVANZA across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Robust Profit Growth (2700.00%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (1745.33%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

9 factors identified

Below-Average Return on Equity (-15.58%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-2.77%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (1.94%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Limited Growth History (-5.02% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Elevated Debt Levels (D/E: 2.20)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Weak Interest Coverage (0.07x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-2.09 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Low Promoter Commitment (20.02%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Vivanza Biosciences Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Vivanza Biosciences Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
12.4/100
2
₹8.80
-15.58%
Poor
-2.77%
Poor
2.2
Poor
-5.02%
Poor
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Vivanza Biosciences Ltd PE Ratio History

Historical price-to-earnings ratio for VIVANZA — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20240.14₹3.4224.4x
FY 20230.15₹10.7771.8x
FY 20220.08₹15.60188x
FY 20210.02₹17.91942.9x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Vivanza Biosciences Ltd Quarterly Performance

Latest quarterly metrics for VIVANZA — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

1745.33%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

2700.00%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-5.02%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Vivanza Biosciences Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for VIVANZA — calculated from daily price history

31RSI 14
Neutral — RSI 31

Momentum is balanced — neither overbought nor oversold.

SMA 50
2
▼ Price below SMA 50 — Short-term bearish
SMA 200
2
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
21K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Vivanza Biosciences Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Vivanza Biosciences Ltd (VIVANZA) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Vivanza Biosciences Ltd

About VIVANZA (Vivanza Biosciences Ltd)

Vivanza Biosciences Ltd is a dynamic pharmaceutical entity deeply rooted in the Indian healthcare landscape. From its base in Ahmedabad, the company channels its energies into the ...meticulous creation of a diverse portfolio of medical products. Vivanza operates at the intersection of research, development, and production, focusing on fulfilling critical needs within the medical community. They are committed to crafting products that meet rigorous quality standards, essential for patient well-being. While maintaining a commitment to traditional manufacturing practices, they also embrace modern techniques to improve efficiency and expand product availability, solidifying their position as a reliable source within the Indian pharmaceutical industry. The company's product line extends beyond just pharmaceuticals, showcasing a commitment to comprehensive medical supplies. Vivanza Biosciences provides a variety of gloves, from the widely used latex surgical and examination options, to latex-free alternatives catering to individuals with specific sensitivities. This variety demonstrates an awareness of the evolving needs of healthcare providers and a dedication to offering solutions for a wide range of medical settings. By producing surgical products alongside its pharmaceutical offerings, Vivanza aims to provide a holistic approach to patient care, catering to both preventative and interventional needs. This diverse approach makes them a valued contributor to the accessibility of essential medical products in the Indian market. With a history dating back to 1982, Vivanza Biosciences Ltd leverages decades of experience within the pharmaceutical sector. This established presence gives them a unique perspective on the evolving challenges and opportunities within the Indian healthcare system. Their consistent focus on manufacturing and distributing quality products has helped them build lasting relationships with healthcare providers and patients. While constantly striving for innovation and improvement, they remain grounded in their commitment to reliability and accessibility. As the Indian pharmaceutical landscape continues to advance, Vivanza Biosciences is strategically positioned to adapt and contribute meaningfully to the nation's healthcare needs.

Company Details

Symbol:VIVANZA
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Jainil Raseshkumar Bhatt
CFO & Director
Mr. Jayendra Amichand Mehta
MD & Executive Director
Chaitra Arora C.S.
Company Secretary & Compliance Officer

VIVANZA Share Price: Frequently Asked Questions

What is the current share price of Vivanza Biosciences Ltd?

Vivanza Biosciences Ltd (VIVANZA) trades at ₹1.81 on NSE and BSE. Market cap ₹8.80 (Cr). Educational data only.

What is the P/E ratio of Vivanza Biosciences Ltd?

Vivanza Biosciences Ltd has a P/E of N/Ax vs industry average 31.77x.

What is the Bull Run score for Vivanza Biosciences Ltd?

Vivanza Biosciences Ltd has a Bull Run score of 12.4/100 based on 25+ financial parameters.

Does Vivanza Biosciences Ltd pay dividends?

Vivanza Biosciences Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Vivanza Biosciences Ltd?

Vivanza Biosciences Ltd has ROE of -15.58%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Vivanza Biosciences Ltd?

Vivanza Biosciences Ltd has debt-to-equity of 2.20.

Is Vivanza Biosciences Ltd a good investment?

Bull Run gives Vivanza Biosciences Ltd a score of 12.4/100. This is not investment advice — consult a SEBI-registered advisor.